Agree Realty (ADC - Free Report) came out with quarterly funds from operations (FFO) of $1.15 per share, beating the Zacks Consensus Estimate of $1.14 per share. This compares to FFO of $1.1 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an FFO surprise of +0.88%. A quarter ago, it was expected that this real estate investment trust would post FFO of $1.13 per share when it actually produced FFO of $1.14, delivering a surprise of +0.88%.
Over the last four quarters, the company has surpassed consensus FFO estimates four times.
Agree Realty, which belongs to the Zacks REIT and Equity Trust - Retail industry, posted revenues of $213.88 million for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 1.33%. This compares to year-ago revenues of $183.22 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.
Agree Realty shares have lost about 8.6% since the beginning of the year versus the S&P 500's gain of 12.4%.
What's Next for Agree Realty?While Agree Realty has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Agree Realty was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $1.16 on $216.85 million in revenues for the coming quarter and $4.56 on $833.97 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Retail is currently in the top 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Simon Property (SPG - Free Report) , another stock in the same industry, has yet to report results for the quarter ended September 2026. The results are expected to be released on November 5.
This shopping mall real estate investment trust is expected to post quarterly earnings of $3.32 per share in its upcoming report, which represents a year-over-year change of +3.1%. The consensus EPS estimate for the quarter has been revised 0% lower over the last 30 days to the current level.
Simon Property's revenues are expected to be $1.73 billion, up 8% from the year-ago quarter.
CoreCap Advisors ve třetím čtvrtletí snížila svůj podíl ve společnosti Agree Realty o 94,8 % prodejem 76 056 akcií; zůstalo jí 4 213 akcií v hodnotě 281 000 USD.
CoreCap Advisors LLC lessened its position in Agree Realty Corporation (NYSE:ADC – Free Report) by 94.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,213 shares of the real estate investment trust’s stock after selling 76,056 shares during the quarter. CoreCap Advisors LLC’s holdings in Agree Realty were worth $281,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently bought and sold shares of ADC. Clearstead Trust LLC bought a new position in Agree Realty in the second quarter valued at $33,000. Elevation Wealth Partners LLC boosted its stake in shares of Agree Realty by 172.2% during the 3rd quarter. Elevation Wealth Partners LLC now owns 430 shares of the real estate investment trust’s stock worth $29,000 after buying an additional 272 shares during the last quarter. CX Institutional boosted its stake in shares of Agree Realty by 852.2% during the 3rd quarter. CX Institutional now owns 438 shares of the real estate investment trust’s stock worth $29,000 after buying an additional 392 shares during the last quarter. Wealth Enhancement Trust Services Inc. acquired a new position in shares of Agree Realty during the 3rd quarter worth about $32,000. Finally, Transamerica Financial Advisors LLC bought a new position in shares of Agree Realty in the 2nd quarter valued at about $45,000. Institutional investors own 97.83% of the company’s stock.
Analysts Set New Price Targets A number of research firms recently issued reports on ADC. Barclays lifted their target price on Agree Realty from $84.00 to $85.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 22nd. Truist Financial began coverage on Agree Realty in a research report on Thursday, October 1st. They set a “buy” rating and a $75.00 price target for the company. Robert W. Baird set a $83.00 price target on Agree Realty in a research note on Friday, July 31st. Wall Street Zen lowered Agree Realty from a “hold” rating to a “sell” rating in a research report on Saturday, August 1st. Finally, Weiss Ratings lowered Agree Realty from a “buy (b)” rating to a “buy (b-)” rating in a research report on Thursday, September 17th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $82.81.
Check Out Our Latest Research Report on Agree Realty Agree Realty Trading Up 0.3% Agree Realty stock opened at $66.17 on Tuesday. Agree Realty Corporation has a 52 week low of $64.43 and a 52 week high of $82.08. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.82 and a current ratio of 0.82. The stock has a market capitalization of $8.23 billion, a P/E ratio of 35.58, a PEG ratio of 2.21 and a beta of 0.42. The stock has a 50-day simple moving average of $70.99 and a 200 day simple moving average of $74.56.
Agree Realty (NYSE:ADC – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The real estate investment trust reported $0.44 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.48 by ($0.04). Agree Realty had a net margin of 28.84% and a return on equity of 3.90%. The business had revenue of $216.33 million during the quarter, compared to the consensus estimate of $204.53 million. During the same quarter in the prior year, the company earned $1.06 EPS. Agree Realty’s quarterly revenue was up 16.8% on a year-over-year basis. Agree Realty has set its FY 2026 guidance at 4.570-4.590 EPS. Analysts expect that Agree Realty Corporation will post 4.45 earnings per share for the current year.
Agree Realty Announces Dividend The firm also recently declared a monthly dividend, which will be paid on Wednesday, October 14th. Investors of record on Wednesday, September 30th will be paid a $0.2670 dividend. This represents a $3.20 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date is Wednesday, September 30th. Agree Realty’s dividend payout ratio is 172.04%.
Insider Activity at Agree Realty In other Agree Realty news, insider Craig Erlich purchased 1,000 shares of the company’s stock in a transaction that occurred on Monday, September 21st. The shares were acquired at an average price of $67.55 per share, for a total transaction of $67,550.00. Following the purchase, the insider owned 60,388 shares in the company, valued at approximately $4,079,209.40. The trade was a 1.68% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director John Rakolta, Jr. purchased 20,000 shares of the business’s stock in a transaction on Wednesday, September 16th. The shares were acquired at an average cost of $68.78 per share, with a total value of $1,375,600.00. Following the acquisition, the director directly owned 654,602 shares in the company, valued at approximately $45,023,525.56. The trade was a 3.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 48,496 shares of company stock worth $3,418,670. Company insiders own 1.80% of the company’s stock.
Agree Realty Profile (Free Report)
Agree Realty Corporation is a real estate investment trust (REIT) that owns, develops, acquires and manages retail properties leased primarily under long-term, single-tenant net lease agreements. Under these arrangements, tenants generally assume responsibility for property-level expenses such as taxes, insurance and maintenance.
The company focuses on necessity-based retail properties, including locations occupied by grocery stores, home improvement retailers, discount retailers, pharmacies and other service-oriented businesses.
See Also Five stocks we like better than Agree Realty Salesforce Just Got a Rare Double Upgrade—What Changed? OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit 3 REITs That May Win in a Higher Interest Rate Environment Want to see what other hedge funds are holding ADC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agree Realty Corporation (NYSE:ADC – Free Report).
Receive News & Ratings for Agree Realty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agree Realty and related companies with MarketBeat.com's FREE daily email newsletter.
Crescent Biopharma získala od FDA schválení IND pro CR-002, topoisomerázový ADC cílený na PD-L1 pro pokročilé solidní nádory. Studie APOLLO fáze 1/2 má začít ve 4. čtvrtletí 2026.
Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026
Initial clinical data expected in the second half of 2027
WALTHAM, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a clinical-stage biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for CR-002, a topoisomerase inhibitor antibody drug-conjugate (ADC) targeting programmed cell death ligand 1 (PD-L1), being developed for the treatment of advanced solid tumors.
“FDA clearance of the CR-002 IND is an important milestone for Crescent and is the third distinct program in our portfolio to enter the clinic,” said Ellie Im, M.D., chief medical officer of Crescent. “The strong scientific rationale and encouraging preclinical profile of CR-002 underscores its promise in addressing a range of solid tumors. We look forward to initiating the APOLLO trial this quarter and working with global investigators to generate important clinical insights and advance our mission of bringing new treatment options to patients living with difficult-to-treat cancers.”
The Phase 1/2 APOLLO global clinical trial plans to enroll patients in the United States, Europe and Asia Pacific with advanced solid tumors, including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and various gastrointestinal and gynecological tumors. The study’s dose escalation and tumor-specific backfill cohorts are expected to enroll approximately 200 participants with the opportunity for additional participants in expansion cohorts. Crescent anticipates reporting initial clinical data from the APOLLO trial in the second half of 2027, including safety, pharmacokinetic and preliminary antitumor activity in multiple tumor types.
About CR-002
CR-002, internally developed in collaboration with Paragon Therapeutics, is a topoisomerase inhibitor ADC directed to PD-L1, a validated target known to have high expression in multiple solid tumors and comparatively limited expression in healthy tissue. CR-002 incorporates a PD-L1 antibody selected for high internalization to facilitate payload release in target cells and a linker designed for intracellular cleavage and high stability in circulation, an approach intended to concentrate payload delivery in tumor tissue. APOLLO, a global Phase 1/2 trial of CR-002 in patients with solid tumors, is anticipated to commence in the fourth quarter of 2026. Crescent also plans to evaluate CR-002 in combination with CR-001, its PD-1 x VEGF bispecific antibody, as part of its efforts to evaluate synergistic ADC and immuno-oncology combinations.
About Crescent Biopharma
Crescent Biopharma’s vision is to build a world leading oncology company bringing the next wave of therapies for cancer patients. The Company’s clinical-stage pipeline includes its lead program, a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates (ADCs). By leveraging multiple modalities and established targets, Crescent aims to rapidly advance potentially transformative therapies as single agents and as part of combination regimens to treat a range of solid tumors. For more information, visit www.crescentbiopharma.com and follow the Company on LinkedIn and X.
Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Crescent’s expectations, beliefs, or strategies regarding the future of its pipeline and business including, without limitation: the initiation, design, timing, and success of the Phase 1/2 global APOLLO trial; the potential for CR-002 to treat a range of solid tumors; and anticipated timing of reporting proof-of concept data from the APOLLO trial. Forward-looking statements generally relate to future events or future financial or operating performance. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects and involve a number of risks, uncertainties or other assumptions that may cause actual performance to be materially different from those expressed or implied by these forward-looking statements. Risks and uncertainties include, but are not limited to: the expected benefits of, and opportunities related to, the strategic partnership between Crescent and Kelun-Biotech may not be realized or may take longer to realize than anticipated; Crescent’s limited operating history, including with respect to clinical trials; Crescent’s historical losses and any future ability to generate revenue; Crescent’s ability to raise capital to support its business plans; risks associated with clinical development and regulatory approval; risks related to Crescent’s intellectual property; Crescent’s reliance on third parties, including to help develop its product candidates, run its clinical trials, and manufacture its product candidates; significant disruptions of information technology systems or breaches of data security, litigation and regulatory risks; risks related to the current macroeconomic environment, including fluctuating interest rates, barriers to trade, changes to fiscal and monetary policy or government budget dynamics, geopolitical factors, including the ongoing conflicts in Iran and between Russia and Ukraine and the responses thereto, and supply chain disruptions, as well as those factors more fully described in Crescent’s most recent filings with the Securities and Exchange Commission (including its Quarterly Report on Form 10-Q), and Crescent’s other filings with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Crescent’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Except as required by law, Crescent does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements.
Agree Realty Corporation (NYSE:ADC – Get Free Report) announced a monthly dividend on Thursday, September 10th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.2670 per share by the real estate investment trust on Wednesday, October 14th. This represents a $3.20 dividend on an annualized basis and a yield of 4.8%. The ex-dividend date of this dividend is Wednesday, September 30th.
Agree Realty has increased its dividend by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 1 consecutive years. Agree Realty has a dividend payout ratio of 162.4% indicating that the company cannot currently cover its dividend with earnings alone and is relying on its balance sheet to cover its dividend payments. Equities research analysts expect Agree Realty to earn $4.67 per share next year, which means the company should continue to be able to cover its $3.20 annual dividend with an expected future payout ratio of 68.5%.
Agree Realty Trading Down 0.0% Agree Realty stock opened at $67.45 on Monday. Agree Realty has a one year low of $66.50 and a one year high of $82.08. The company’s fifty day moving average price is $73.99 and its two-hundred day moving average price is $75.53. The company has a debt-to-equity ratio of 0.60, a current ratio of 0.82 and a quick ratio of 0.82. The company has a market capitalization of $8.39 billion, a price-to-earnings ratio of 36.26, a PEG ratio of 2.20 and a beta of 0.46.
Agree Realty (NYSE:ADC – Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The real estate investment trust reported $0.44 earnings per share for the quarter, missing analysts’ consensus estimates of $0.48 by ($0.04). The company had revenue of $216.33 million during the quarter, compared to analyst estimates of $204.53 million. Agree Realty had a return on equity of 3.90% and a net margin of 28.84%.Agree Realty’s quarterly revenue was up 16.8% on a year-over-year basis. During the same period in the prior year, the firm earned $1.06 EPS. Agree Realty has set its FY 2026 guidance at 4.570-4.590 EPS. On average, analysts forecast that Agree Realty will post 4.45 earnings per share for the current fiscal year. Agree Realty Company Profile (Get Free Report)
Agree Realty Corporation (NYSE: ADC) is a real estate investment trust that owns, develops, acquires and manages retail properties. The company primarily invests in freestanding, net-leased properties occupied by nationally recognized and regionally established retailers.
Under a net lease, tenants generally pay expenses such as property taxes, insurance and maintenance in addition to rent. Agree Realty’s portfolio is focused largely on essential retail locations, including stores serving everyday consumer needs.
Further Reading Five stocks we like better than Agree Realty 3 Niche Growth Stocks With an Edge Their Rivals Can’t Ignore 3 Dividend Stocks With Higher Yields and Room for More Payout Growth Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes 2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind
Receive News & Ratings for Agree Realty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agree Realty and related companies with MarketBeat.com's FREE daily email newsletter.
Agree Realty Corporation (NYSE:ADC – Get Free Report) CEO Joey Agree acquired 7,360 shares of the company’s stock in a transaction on Wednesday, September 16th. The shares were acquired at an average price of $68.06 per share, for a total transaction of $500,921.60. Following the completion of the acquisition, the chief executive officer directly owned 682,465 shares in the company, valued at $46,448,567.90. The trade was a 1.09% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Agree Realty Stock Performance Agree Realty stock opened at $68.02 on Friday. The stock has a market cap of $8.46 billion, a P/E ratio of 36.57, a price-to-earnings-growth ratio of 2.23 and a beta of 0.46. The company has a current ratio of 0.82, a quick ratio of 0.82 and a debt-to-equity ratio of 0.60. The stock has a 50 day moving average of $75.17 and a 200-day moving average of $76.06. Agree Realty Corporation has a 52 week low of $67.70 and a 52 week high of $82.08.
Agree Realty (NYSE:ADC – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The real estate investment trust reported $0.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.48 by ($0.04). Agree Realty had a return on equity of 3.90% and a net margin of 28.84%.The company had revenue of $216.33 million during the quarter, compared to the consensus estimate of $204.53 million. During the same quarter last year, the firm posted $1.06 EPS. The firm’s quarterly revenue was up 16.8% on a year-over-year basis. Agree Realty has set its FY 2026 guidance at 4.570-4.590 EPS. On average, analysts expect that Agree Realty Corporation will post 4.45 EPS for the current fiscal year.
Agree Realty Announces Dividend The business also recently announced a monthly dividend, which will be paid on Wednesday, October 14th. Stockholders of record on Wednesday, September 30th will be paid a $0.267 dividend. This represents a c) dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date is Wednesday, September 30th. Agree Realty’s dividend payout ratio is 172.04%. Agree Realty News Summary Here are the key news stories impacting Agree Realty this week:
Positive Sentiment: CEO Joey Agree bought 7,360 shares for approximately $501,000, while Director John Rakolta Jr. purchased 20,000 shares worth about $1.38 million. The roughly $1.9 million in combined insider buying may signal that company leadership considers the recent weakness an attractive entry point. Agree Realty trades higher after reporting approximately $2 million in insider buy transactions Positive Sentiment: Stifel Nicolaus lowered its price target from $84.00 to $81.50 but maintained a “buy” rating. The revised target still implies meaningful upside from recent trading levels, providing some support for the stock. Stifel lowers Agree Realty price target while maintaining buy rating Positive Sentiment: Agree Realty declared its regular monthly dividend of $0.267 per share, payable October 14 to shareholders of record September 30. The dividend supports ADC’s appeal as an income-oriented real estate investment trust. Neutral Sentiment: The company priced $400 million of 5.650% senior unsecured notes due 2036, with an effective yield of 5.849%. The proceeds improve financial flexibility and can fund corporate activities, although the debt will add interest expense in a higher-cost financing environment. Agree Realty announces pricing of $400 million of senior unsecured notes Negative Sentiment: Mizuho cut its price target from $80.00 to $72.00 and assigned a “neutral” rating. Although the new target remains above recent levels, the reduction signals more cautious expectations and may weigh on investor sentiment. Mizuho lowers Agree Realty price target and maintains neutral rating Analyst Ratings Changes A number of equities analysts recently commented on ADC shares. Wall Street Zen downgraded Agree Realty from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Weiss Ratings cut Agree Realty from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday. Robert W. Baird set a $83.00 target price on Agree Realty in a report on Friday, July 31st. Stifel Nicolaus decreased their target price on Agree Realty from $84.00 to $81.50 and set a “buy” rating for the company in a research report on Friday. Finally, Jefferies Financial Group assumed coverage on Agree Realty in a report on Monday, June 1st. They issued a “buy” rating and a $84.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $83.25.
Get Our Latest Report on Agree Realty
Institutional Inflows and Outflows Several institutional investors and hedge funds have recently bought and sold shares of ADC. Community Bank of Raymore raised its holdings in shares of Agree Realty by 11.5% during the second quarter. Community Bank of Raymore now owns 44,624 shares of the real estate investment trust’s stock valued at $3,380,000 after buying an additional 4,600 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Agree Realty in the 2nd quarter worth approximately $51,000. NewEdge Advisors LLC increased its position in Agree Realty by 2,367.6% in the 2nd quarter. NewEdge Advisors LLC now owns 2,739 shares of the real estate investment trust’s stock valued at $207,000 after acquiring an additional 2,628 shares during the period. Squarepoint Ops LLC increased its position in Agree Realty by 103.4% in the 2nd quarter. Squarepoint Ops LLC now owns 86,373 shares of the real estate investment trust’s stock valued at $6,542,000 after acquiring an additional 43,912 shares during the period. Finally, Arizona State Retirement System raised its stake in Agree Realty by 4.9% during the 2nd quarter. Arizona State Retirement System now owns 33,140 shares of the real estate investment trust’s stock valued at $2,510,000 after acquiring an additional 1,555 shares in the last quarter. Institutional investors own 97.83% of the company’s stock.
About Agree Realty (Get Free Report)
Agree Realty Corporation (NYSE: ADC) is a real estate investment trust that owns, develops, acquires and manages retail properties. The company primarily invests in freestanding, net-leased properties occupied by nationally recognized and regionally established retailers.
Under a net lease, tenants generally pay expenses such as property taxes, insurance and maintenance in addition to rent. Agree Realty’s portfolio is focused largely on essential retail locations, including stores serving everyday consumer needs.
Recommended Stories Five stocks we like better than Agree Realty Lennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. Housing Priced for a Pullback or More Gains? These 3 Stocks Are Testing the Limits These 3 Agentic AI Stocks Have More Than Hype Behind Their Growth Stories Not Just Banks: 3 Trading Stocks to Watch After the Fed Rate Hike
Receive News & Ratings for Agree Realty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agree Realty and related companies with MarketBeat.com's FREE daily email newsletter.
Whitehawk Therapeutics oznámila data, podle nichž PTK7 zůstává po standardní léčbě stabilním a klinicky relevantním cílem pro ADC u předléčeného EGFR wild-type NSCLC. To podporuje vývoj HWK-007 ve fázi 1.
PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as
a Target in Second- or Later-Line EGFR NSCLC
Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed
ADC Currently in Phase 1 Development
, /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant ADC target in patients with pretreated, EGFR wild-type non-small cell lung cancer (NSCLC). The data will be presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place September 12-15, 2026, in Seoul, Republic of Korea.
In tumor samples from patients with EGFR wild-type lung adenocarcinoma, PTK7 expression remained largely stable following standard-of-care (SoC) treatments, including chemotherapy and immunotherapy, and demonstrated less treatment associated variation than several other ADC targets in late-stage development. PTK7 expression was also generally consistent regardless of the presence or absence of other actionable genomic alterations (AGA). These findings indicate PTK7 remains available for targeted ADCs for patients that have progressed through multiple lines of SoC therapy and across clinically relevant subgroups.
A separate analysis of patients with advanced EGFR wild-type lung adenocarcinoma found that real-world overall survival was not impacted based on PTK7-expression, supporting PTK7 as a target-engagement biomarker for ADC payload delivery independent of prognosis in NSCLC.
"The development strategy for our PTK7-directed ADC, HWK-007, is grounded in understanding not only where PTK7 is expressed, but also how that expression behaves in a real-world treatment setting," said Margaret Dugan, MD, Chief Medical Officer of Whitehawk Therapeutics. "The stability of PTK7 expression after standard of care therapies, in particular compared to other therapies in late-stage development, add important translational context as we evaluate HWK-007 in patients with EGFR wild-type NSCLC."
Key Findings:
Durable and Treatment-Agnostic PTK7 Expression in EGFR Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development
PTK7 expression remained largely stable following standard-of-care immunotherapy, chemotherapy, chemoimmunotherapy and tyrosine kinase inhibitor treatment, suggesting that the target may remain available for PTK7-directed therapy after prior treatment. Stable PTK7 expression is also observed in paired tumor samples. PTK7 demonstrated less treatment-associated variation than several late-stage ADC targets, including MET, PD-L1 and ITGB6. PTK7 expression was generally consistent across tumors with or without other AGA, including KRAS G12C, ALK and MET alterations, suggesting relevance of PTK7 as an ADC target across both AGA+ and AGA- NSCLC subgroups. Association Between PTK7 Expression and Real-World Survival in Pretreated Patients With EGFR Wild-Type Lung Adenocarcinoma
PTK7 expression was not independently associated with real-world overall survival or progression-free survival in patients with advanced EGFR wild-type lung adenocarcinoma receiving second- or later-line therapy, supporting PTK7 as a target-engagement biomarker rather than a marker of prognosis. Clinical outcomes were driven primarily by established prognostic factors, including Eastern Cooperative Oncology Group performance status and extent of prior therapy. PTK7-low tumors were enriched for KEAP1 and STK11 alterations, suggesting biological heterogeneity of EGFR wild-type NSCLC. "Understanding whether a therapeutic target remains present after prior treatment is particularly important in advanced lung cancer, where patients often receive multiple lines of therapy," said Aaron E. Lisberg, MD, Associate Professor of Medicine at the David Geffen School of Medicine at UCLA. "The stability of PTK7 expression across standard treatments and clinically relevant molecular subgroups supports further investigation of PTK7-directed ADCs in patients with previously treated EGFR wild-type lung adenocarcinoma."
Poster Presentation Details:
Title: Durable and Treatment-Agnostic PTK7 Expression in EGFR Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development
Poster: P2.241
Presenter: Aaron E. Lisberg, MD, University of California Los Angeles, Los Angeles, CA, USA
Date & Time: Monday, September 14, 2026, at 10:30 AM KST
Title: Association Between PTK7 Expression and Real-World Survival in Pretreated Patients With EGFR Wild-Type Lung Adenocarcinoma
Poster: P2.147
Presenter: Grace Dy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA
Date & Time: Monday, September 14, 2026, at 10:30 AM KST
HWK‑007 is PTK7-directed, next-generation ADC being evaluated in an ongoing Phase 1 clinical trial in patients with non-squamous, EGFR wild-type NSCLC, platinum-resistant ovarian cancer and endometrial cancer (NCT07444814).
These analyses were conducted as part of a previously announced collaboration between Whitehawk and Tempus AI. The posters will be accessible on the Presentations page of the Investors & News section of the Company's website at www.whitehawktx.com.
About Whitehawk Therapeutics
Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved cancer treatments. Whitehawk's portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.
Whitehawk's underlying ADC platform leverages CPT113 as the core linker-payload technology, enhanced with its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process to support improved stability and therapeutic index. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn. Any references to the Company's website or other online resources are provided solely for convenience and are not incorporated by reference into this press release. Investors should rely only on the information contained in this press release and the Company's filings with the Securities and Exchange Commission.
Forward-Looking Statements
This press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to the potential therapeutic value and market opportunity for HWK-007 and expectations regarding the beneficial characteristics, design features and the potential targeted markets with respect to HWK-007. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties associated with preclinical and clinical development of HWK-007 .
Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov.
All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
ADC Therapeutics uvedla za 2. čtvrtletí tržby z produktu ZYNLONTA ve výši 18,6 mil. USD, ale FDA vznesla „podstatné obavy“ k potvrzovací studii LOTIS-5. Firma přesto nečeká dopad na stávající monoterapeutickou indikaci.
ADC Therapeutics NYSE: ADCT reported second-quarter 2026 net product revenue of $18.6 million for ZYNLONTA, up from $18.1 million in the prior-year period, while executives said the treatment’s commercial performance remained broadly consistent with recent quarters.
The company also said it is reassessing the regulatory path for its LOTIS-5 confirmatory study after receiving FDA feedback that raised “substantial concerns” about the benefit-risk profile and verification of the treatment benefit observed in the trial.
Get ADC Therapeutics alerts:
ZYNLONTA is currently approved under the FDA’s accelerated approval pathway as a single-agent treatment for patients with third-line-plus diffuse large B-cell lymphoma, or DLBCL. Chief Executive Officer Ameet Mallik said the company remains confident in the therapy’s role in that setting and does not expect the LOTIS-5 feedback to affect the existing monotherapy indication.
“The discussions with the FDA were related only to the trial,” Mallik said during the company’s earnings call. “There was no feedback at all about the single agent.”
FDA Raises Concerns on LOTIS-5 LOTIS-5 is a Phase III confirmatory trial evaluating ZYNLONTA in combination with rituximab against R-GemOx in patients with second-line DLBCL. The company said the study met its primary endpoint of progression-free survival and announced top-line results in June.
However, following an early-August pre-supplemental biologics license application meeting, Chief Medical Officer Mohamed Zaki said the FDA expressed substantial concerns regarding the benefit-risk assessment and verification of the benefit observed in the study.
ADC Therapeutics said it is assessing whether additional data, risk-management measures, or potential label modifications could address the agency’s concerns. The company did not provide a timeline for an updated regulatory strategy.
In response to analyst questions regarding serious infections in LOTIS-5, Mallik said the primary type of infections involved bacterial infections. He noted that LOTIS-7, a separate study of ZYNLONTA in combination with glofitamab, includes recommendations for prophylaxis and vaccinations covering viral, fungal and bacterial infections, including Pneumocystis jirovecii pneumonia and herpes virus. Those measures were not included in the LOTIS-5 protocol.
ADC Therapeutics submitted full LOTIS-5 data for presentation at the American Society of Hematology meeting and is pursuing publication. The company also expects to seek potential compendia inclusion beginning in 2027.
LOTIS-7 Enrollment Completed; Breakthrough Request Planned The company completed enrollment of 100 patients at the selected ZYNLONTA dose level in LOTIS-7, a Phase Ib study evaluating ZYNLONTA plus glofitamab in second-line-plus DLBCL. ADC Therapeutics submitted an abstract containing data from most of the enrolled population to ASH.
Mallik said the company believes the submitted data show compelling efficacy and safety, while Zaki said the combination has the potential to be a best-in-class regimen. The company did not disclose the updated data during the call.
ADC Therapeutics plans to submit a request for breakthrough therapy designation for the ZYNLONTA-glofitamab combination this year and is evaluating a potential Phase III study. Mallik said the company is still gathering feedback from the medical community and would need to work with the FDA on a final trial design, making it too early to discuss timing or cost.
Management said it does not expect the safety findings from LOTIS-5 to have implications for LOTIS-7 or for potential compendia inclusion of the latter regimen, citing differences in the study regimens and preventive-infection protocols. Mallik referenced the company’s prior December disclosure, which showed approximately 4% grade-five events among 49 patients in the earlier LOTIS-7 dataset.
Beyond DLBCL, the company said updated investigator-initiated trial data in marginal zone lymphoma were submitted to ASH. Updated follicular lymphoma data are anticipated in the second quarter of 2027. ADC Therapeutics also plans to assess regulatory paths in indolent lymphomas and expects to seek breakthrough designation in marginal zone lymphoma.
Costs Decline as Reorganization Takes Effect ADC Therapeutics reported total operating expenses of $44.7 million for the second quarter. On a non-GAAP basis, adjusted operating expenses were $37.2 million, a 22% decline from the prior-year quarter, primarily due to lower research and development expenses.
The company recorded a GAAP net loss of $16.6 million, compared with a net loss of $56.6 million a year earlier. Its non-GAAP adjusted net loss was $16.3 million, compared with $28.7 million in the second quarter of 2025.
In June, ADC Therapeutics announced a strategic reorganization that included a workforce reduction of approximately 17% and additional operational efficiencies. The company expects the actions to generate about $10 million in annualized cost savings while maintaining its commercial footprint for ZYNLONTA in third-line-plus DLBCL.
Cash and cash equivalents totaled $219.1 million at June 30, down from $231 million at March 31, primarily because of cash used in operations. The company said its cash runway is expected to extend at least into 2028.
Since receiving accelerated approval in 2021, ZYNLONTA monotherapy has been used to treat approximately 5,000 patients in the United States, according to Mallik. Management said it expects the therapy’s current commercial performance to remain stable and sees potential growth beginning in 2027 through expansion into earlier DLBCL treatment lines and indolent lymphomas.
About ADC Therapeutics (NYSE:ADCT)ADC Therapeutics SA is a clinical-stage biopharmaceutical company focused on the discovery and development of highly targeted antibody-drug conjugates (ADCs) designed to treat hematological malignancies such as non-Hodgkin lymphoma and acute myeloid leukemia. By marrying the specificity of monoclonal antibodies with potent cytotoxic payloads, the company aims to maximize tumor cell eradication while limiting off-target toxicity.
At the core of ADC Therapeutics' portfolio is loncastuximab tesirine-lpyl, a CD19-directed ADC that received accelerated approval from the U.S.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Should You Invest $1,000 in ADC Therapeutics Right Now?Before you consider ADC Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ADC Therapeutics wasn't on the list.
While ADC Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Agree Realty Corporation (ADC) Q2 2026 Earnings Call July 31, 2026 10:00 AM EDT
Company Participants
Reuben Treatman - Senior Director of Corporate Finance
Joey Agree - President, CEO & Director
Peter Coughenour - CFO, Secretary & Investor Relations Professional
Conference Call Participants
Michael Goldsmith - UBS Investment Bank, Research Division
William John Kilichowski - Wells Fargo Securities, LLC, Research Division
James Kammert - Evercore ISI Institutional Equities, Research Division
Spenser Allaway - Green Street Advisors, LLC, Research Division
Eric Borden - BMO Capital Markets Equity Research
Robert Stevenson
Ronald Kamdem - Morgan Stanley, Research Division
Presentation
Operator
Good morning, and welcome to the Agree Realty Second Quarter 2026 Earnings Call. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Note this event is being recorded. I would now like to turn the conference over to Reuben Treatman, Senior Director of Corporate Finance. Please go ahead, Reuben.
Reuben Treatman
Senior Director of Corporate Finance
Thank you. Good morning, everyone, and thank you for joining us for Agree Realty's Second Quarter 2026 Earnings Call. Before turning the call over to Joey and Peter to discuss our results for the quarter, let me first run through the cautionary language. Please note that during this call, we will make certain statements that may be considered forward-looking under Federal Securities Law including statements related to our updated 2026 guidance.
Our actual results may differ significantly from the matters discussed in any forward-looking statements for a number of reasons. Please see yesterday's earnings release and our SEC filings, including our latest annual report on Form 10-K for a discussion of various risks and uncertainties underlying our forward-looking statements. In addition, we discuss non-GAAP financial measures, including core funds from operations or core FFO, adjusted funds from operations, or AFFO, net debt to enterprise value, fixed charge coverage ratio and pro forma net debt to
Agree Realty ve druhém čtvrtletí investovala přes 500 milionů USD, což je rekord, a zvýšila celoroční investiční výhled na 1,6 až 1,8 miliardy USD. Zároveň zvedla výhled AFFO na akcii na 4,57 až 4,59 USD.
3 Stocks to Buy After Heavy Insider BuyingAgree Realty NYSE: ADC reported record second-quarter investment activity and raised its full-year outlook, citing strong acquisition, development and portfolio performance.
President and CEO Joey Agree said the company invested more than $500 million across its three external growth platforms during the quarter, calling it a company record. The investment activity included $451 million of acquisitions involving 82 retail net-lease assets, along with development and developer funding platform activity.
Get Agree Realty alerts:
“The combination of real estate attributes, credit composition, and lease terms similarly represent the highest quality quarter in our company’s history,” Agree said.
Guidance Raised as Investment Pipeline Expands The company raised its full-year 2026 investment-volume guidance to a range of $1.6 billion to $1.8 billion. At the midpoint, the updated range exceeds the company’s investment activity last year and represents a 24% increase from its initial guidance for 2026, according to Agree.
Agree Realty also increased its full-year adjusted funds from operations, or AFFO, per-share guidance to $4.57 to $4.59. The midpoint was raised by $0.02 and implies nearly 6% year-over-year growth, CFO Peter Coughenour said.
Core FFO per share was $1.13 in the second quarter, up 7.5% from a year earlier. AFFO per share was $1.14, an increase of 7.4% year over year.
Coughenour said the updated outlook reflects higher investment activity and continued portfolio strength. The company now assumes 25 basis points of credit and occupancy loss for the year, at the low end of its prior 25-to-50-basis-point range. Through the first half of the year, Agree Realty experienced 10 basis points of fully loaded credit and occupancy loss.
Acquisitions Emphasized Retail Credit and Ground Leases Second-quarter acquisitions were concentrated in sectors including auto parts, home improvement, grocery, farm and rural supply, and convenience stores. Notable investments included three Walmart Supercenter ground leases in Missouri, Ohio and Wisconsin; a Walmart Neighborhood Market in Oregon; BP-branded travel centers; and a Home Depot ground lease in New Hampshire.
The acquired assets carried a weighted-average capitalization rate of 7% and a weighted-average lease term of 11.2 years. Investment-grade retailers accounted for more than 73% of annualized base rent acquired during the quarter, while ground leases represented approximately 13.5% of acquired annualized base rent.
Agree said the company has not seen material changes in competitive bidding conditions or cap rates, which he said have remained within a relatively consistent range for about three years. He attributed the company’s ability to acquire higher-credit assets without sacrificing yield to its retailer relationships, internal team and ability to offer multiple transaction structures.
Regarding the approximately $75 million BP transaction, Agree said the assets are large-format travel centers backed by BP North America, which carries an A-minus credit rating. He said the properties are generally located near interstate exits and feature long-term leases with significant escalations.
Ground leases accounted for more than 10% of Agree Realty’s annualized base rent at quarter-end. Agree described them as among his preferred risk-adjusted opportunities because the tenant has typically funded the building while the company owns the land. If a tenant leaves, the building reverts to the landowner, he said.
Development Activity Reaches Record Level The company commenced five development and developer funding projects during the quarter, with anticipated costs of about $88 million. The projects included its seventh and eighth 7-Eleven locations under construction, three Ross Dress for Less sites, two Burlington locations and three TJX concepts.
Through June 30, Agree Realty had commenced more than $105 million of projects, more than three times the volume in the prior-year period. It had 20 projects completed or under construction in the first half, representing roughly $200 million of committed capital.
The company is pursuing a medium-term goal of $250 million in annual development and developer funding platform commencements. Agree said there is a “50/50 shot” that the company reaches that target this year, subject to diligence and timing, and that management would set a new goal if it reaches the target ahead of schedule.
Agree said the development effort centers on tenants already represented in its portfolio, though the company may selectively develop for new tenants. The company continues to focus on off-price retail and large-format convenience stores, he said.
Portfolio Occupancy, Liquidity and Capital Position Agree Realty sold 14 properties during the quarter for approximately $30 million in gross proceeds at a weighted-average cap rate of 7%. The dispositions primarily included three Goodyear locations and four Advance Auto Parts stores. Agree said the properties were non-investment-grade assets with roughly 6.9 years of remaining lease term.
The company executed new leases, extensions or options on about 760,000 square feet during the quarter, producing a recapture rate of approximately 105%. Occupancy increased 10 basis points sequentially to 99.8%, matching a company record.
At quarter-end, the portfolio comprised 2,825 properties in all 50 states and Washington, D.C. Nearly two-thirds of the portfolio was investment grade, while 268 ground leases accounted for more than 10% of annualized base rent.
Year-to-date capital markets activity exceeded $1 billion. During the quarter, the company sold about 400,000 shares of forward equity for approximately $31 million in net proceeds and settled about 4.3 million shares of existing forward equity for nearly $315 million.
Agree Realty ended the quarter with approximately $1.9 billion of liquidity, including cash, forward equity and more than $750 million available under its revolving credit facility, net of commercial-paper borrowings. Pro forma for the settlement of outstanding forward equity, net debt to recurring EBITDA was approximately 3.7 times.
The company also said it has $300 million of forward-starting swaps in place, effectively fixing the base rate for a contemplated 10-year unsecured debt issuance at about 4.1%. Coughenour said the company could issue 10-year debt in the low-5% range based on current conditions and its swaps.
Agree Realty increased its monthly common dividend to $0.267 per share for April through June, equivalent to an annualized dividend of more than $3.20 per share. The dividend represented a 4.3% year-over-year increase and had a second-quarter AFFO payout ratio of 70%.
About Agree Realty (NYSE:ADC)Agree Realty Corporation NYSE: ADC is a publicly traded real estate investment trust headquartered in Chicago, Illinois. Founded in 1971, the company converted to a REIT structure in 2013 and focuses on acquiring, developing and managing a diversified portfolio of retail properties under long-term, triple-net (NNN) leases. Its tenant roster spans national and regional retailers in sectors such as grocery, home improvement, convenience and specialty retail.
Agree Realty's primary business activities include sourcing and underwriting new property acquisitions, originating build-to-suit projects and executing value-add redevelopment programs.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].
Should You Invest $1,000 in Agree Realty Right Now?Before you consider Agree Realty, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agree Realty wasn't on the list.
While Agree Realty currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Agree Realty (ADC - Free Report) came out with quarterly funds from operations (FFO) of $1.14 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to FFO of $1.06 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an FFO surprise of +0.89%. A quarter ago, it was expected that this real estate investment trust would post FFO of $1.12 per share when it actually produced FFO of $1.14, delivering a surprise of +1.79%.
Over the last four quarters, the company has surpassed consensus FFO estimates four times.
Agree Realty, which belongs to the Zacks REIT and Equity Trust - Retail industry, posted revenues of $205.1 million for the quarter ended June 2026, surpassing the Zacks Consensus Estimate by 1.67%. This compares to year-ago revenues of $175.53 million. The company has topped consensus revenue estimates four times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future FFO expectations will mostly depend on management's commentary on the earnings call.
Agree Realty shares have added about 11.6% since the beginning of the year versus the S&P 500's gain of 6.9%.
What's Next for Agree Realty?While Agree Realty has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's FFO outlook. Not only does this include current consensus FFO expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Agree Realty was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus FFO estimate is $1.14 on $206.44 million in revenues for the coming quarter and $4.56 on $818.07 million in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, REIT and Equity Trust - Retail is currently in the top 27% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
Another stock from the same industry, Tanger (SKT - Free Report) , has yet to report results for the quarter ended June 2026. The results are expected to be released on August 4.
This factory outlet mall operator is expected to post quarterly earnings of $0.62 per share in its upcoming report, which represents a year-over-year change of +6.9%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
Tanger's revenues are expected to be $142.51 million, up 6.8% from the year-ago quarter.
